Literature DB >> 26940890

Dynamic behavior of the post-SET loop region of NSD1: Implications for histone binding and drug development.

Sarah E Graham1, Sara E Tweedy2, Heather A Carlson1,3.   

Abstract

NSD1 is a SET-domain histone methyltransferase that methylates lysine 36 of histone 3. In the crystal structure of NSD1, the post-SET loop is in an autoinhibitory position that blocks binding of the histone peptide as well as the entrance to the lysine-binding channel. The conformational dynamics preceding histone binding and the mechanism by which the post-SET loop moves to accommodate the target lysine is currently unknown, although potential models have been proposed. Using molecular dynamics simulations, we have identified potential conformations of the post-SET loop differing from those of previous studies, as well as proposed a model of peptide-bound NSD1. Our simulations illustrate the dynamic behavior of the post-SET loop and the presence of a few distinct conformations. In every case, the post-SET loop remains in an autoinhibitory position blocking the peptide-binding cleft, suggesting that another interaction is required to optimally position NSD1 in an active conformation. This finding provides initial evidence for a mechanism by which NSD1 preferentially binds nucleosomal substrates.
© 2016 The Protein Society.

Entities:  

Keywords:  NSD family; cancer; histone methyltransferase; molecular dynamics; structure-based drug design

Mesh:

Substances:

Year:  2016        PMID: 26940890      PMCID: PMC4838653          DOI: 10.1002/pro.2912

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  33 in total

1.  Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation.

Authors:  Araz Jakalian; David B Jack; Christopher I Bayly
Journal:  J Comput Chem       Date:  2002-12       Impact factor: 3.376

2.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

3.  Strategy to target the substrate binding site of SET domain protein methyltransferases.

Authors:  Kong T Nguyen; Fengling Li; Gennadiy Poda; David Smil; Masoud Vedadi; Matthieu Schapira
Journal:  J Chem Inf Model       Date:  2013-03-01       Impact factor: 4.956

4.  NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines.

Authors:  P O Angrand; F Apiou; A F Stewart; B Dutrillaux; R Losson; P Chambon
Journal:  Genomics       Date:  2001-05-15       Impact factor: 5.736

5.  Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma.

Authors:  María Berdasco; Santiago Ropero; Fernando Setien; Mario F Fraga; Pablo Lapunzina; Régine Losson; Miguel Alaminos; Nai-Kong Cheung; Nazneen Rahman; Manel Esteller
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.

Authors:  Gang G Wang; Ling Cai; Martina P Pasillas; Mark P Kamps
Journal:  Nat Cell Biol       Date:  2007-06-24       Impact factor: 28.824

8.  NSD1 is essential for early post-implantation development and has a catalytically active SET domain.

Authors:  Geetha Vani Rayasam; Olivia Wendling; Pierre-Olivier Angrand; Manuel Mark; Karen Niederreither; Luyan Song; Thierry Lerouge; Gordon L Hager; Pierre Chambon; Régine Losson
Journal:  EMBO J       Date:  2003-06-16       Impact factor: 11.598

Review 9.  Rational approaches to improving selectivity in drug design.

Authors:  David J Huggins; Woody Sherman; Bruce Tidor
Journal:  J Med Chem       Date:  2012-01-12       Impact factor: 7.446

Review 10.  The SET-domain protein superfamily: protein lysine methyltransferases.

Authors:  Shane C Dillon; Xing Zhang; Raymond C Trievel; Xiaodong Cheng
Journal:  Genome Biol       Date:  2005-08-02       Impact factor: 13.583

View more
  10 in total

Review 1.  The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer.

Authors:  Richard L Bennett; Alok Swaroop; Catalina Troche; Jonathan D Licht
Journal:  Cold Spring Harb Perspect Med       Date:  2017-06-01       Impact factor: 6.915

Review 2.  H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.

Authors:  David S Rogawski; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Future Med Chem       Date:  2016-08-22       Impact factor: 3.808

Review 3.  The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.

Authors:  Iuliia Topchu; Rajendra P Pangeni; Igor Bychkov; Sven A Miller; Evgeny Izumchenko; Jindan Yu; Erica Golemis; John Karanicolas; Yanis Boumber
Journal:  Cell Mol Life Sci       Date:  2022-05-09       Impact factor: 9.207

Review 4.  Proximal variants in CCND2 associated with microcephaly, short stature, and developmental delay: A case series and review of inverse brain growth phenotypes.

Authors:  Filomena Pirozzi; Benson Lee; Nicole Horsley; Deepika D Burkardt; William B Dobyns; John M Graham; Maria L Dentici; Claudia Cesario; Jens Schallner; Joseph Porrmann; Nataliya Di Donato; Pedro A Sanchez-Lara; Ghayda M Mirzaa
Journal:  Am J Med Genet A       Date:  2021-06-04       Impact factor: 2.802

5.  Elevated NSD3 histone methylation activity drives squamous cell lung cancer.

Authors:  Gang Yuan; Natasha M Flores; Simone Hausmann; Shane M Lofgren; Vladlena Kharchenko; Maria Angulo-Ibanez; Deepanwita Sengupta; Xiaoyin Lu; Iwona Czaban; Dulat Azhibek; Silvestre Vicent; Wolfgang Fischle; Mariusz Jaremko; Bingliang Fang; Ignacio I Wistuba; Katrin F Chua; Jack A Roth; John D Minna; Ning-Yi Shao; Łukasz Jaremko; Pawel K Mazur; Or Gozani
Journal:  Nature       Date:  2021-02-03       Impact factor: 69.504

6.  DIM5/KMT1 controls fungal insect pathogenicity and genome stability by methylation of histone H3K4, H3K9 and H3K36.

Authors:  Kang Ren; Ya-Ni Mou; Sen-Miao Tong; Sheng-Hua Ying; Ming-Guang Feng
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

Review 7.  NSD2 as a Promising Target in Hematological Disorders.

Authors:  Alba Azagra; César Cobaleda
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

Review 8.  Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?

Authors:  Imène Krossa; Thomas Strub; Andrew E Aplin; Robert Ballotti; Corine Bertolotto
Journal:  Cancers (Basel)       Date:  2022-10-05       Impact factor: 6.575

9.  A loss-of-function variant in SUV39H2 identified in autism-spectrum disorder causes altered H3K9 trimethylation and dysregulation of protocadherin β-cluster genes in the developing brain.

Authors:  Shabeesh Balan; Yoshimi Iwayama; Tetsuo Ohnishi; Mikiko Fukuda; Atsuko Shirai; Ayumi Yamada; Sara Weirich; Maren Kirstin Schuhmacher; Kalarickal Vijayan Dileep; Toshihiro Endo; Yasuko Hisano; Kaoru Kotoshiba; Tomoko Toyota; Takeshi Otowa; Hitoshi Kuwabara; Mamoru Tochigi; Akiko Watanabe; Hisako Ohba; Motoko Maekawa; Manabu Toyoshima; Tsukasa Sasaki; Kazuhiko Nakamura; Masatsugu Tsujii; Hideo Matsuzaki; Kam Y J Zhang; Albert Jeltsch; Yoichi Shinkai; Takeo Yoshikawa
Journal:  Mol Psychiatry       Date:  2021-07-15       Impact factor: 15.992

10.  Whole-exome sequencing reveals novel mutations and epigenetic regulation in hypopharyngeal carcinoma.

Authors:  Ping Wu; Honglong Wu; Yaoyun Tang; Shi Luo; Xing Fang; Chubo Xie; Jian He; Suping Zhao; Xiaofeng Wang; Jiajia Xu; Xi Chen; Dongfang Li; Huanming Yang; Jian Wang
Journal:  Oncotarget       Date:  2017-07-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.